Trial
NCT04227769
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Hospital, Basel, Switzerland
Collaborators
—
Condition
Diabetes Mellitus Type 2 in Obese
Intervention
Anakinra Prefilled Syringe
Why stopped
Too low recruitment in group with patients with diabetes.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-29